Kaplan-Meier | Multivariate | ||||||||
Variables | No. pts | 5y RFS rate (%) | P-value | P-value | H.R. | 95% CL | |||
Age | <70 (yrs.) | 122 | 75 | 0.508 | |||||
≥70 | 102 | 70 | |||||||
Prostate volume | <25 (mL) | 138 | 72 | 0.503 | |||||
≥25 | 86 | 75 | |||||||
Risk group | Low | 54 | 87 | <0.001 | |||||
Intermediate | 111 | 78 | |||||||
High | 59 | 51 | |||||||
T-stage | T1 | 117 | 81 | 0.003 | 0.04 | 0.59 | 0.36 - 0.98 | ||
T2 | 107 | 64 | |||||||
Gleason score | ≤6 | 69 | 82 | 0.003 | Ref. | ≤6 | Ref. | ||
3 + 4 | 79 | 82 | 0.109 | 7 | 0.092 | 1.69 | 0.92 - 3.25 | ||
4 + 3 | 26 | 58 | 0.004 | ||||||
≥8 | 50 | 55 | <0.001 | ≥8 | 0.002 | 3 | 1.51 - 6.12 | ||
Pretreatment PSA | <10 (ng/mL) | 154 | 79 | <0.001 | 0.022 | 0.56 | 0.35 - 0.92 | ||
≥10 | 70 | 58 | |||||||
Nadir PSA | <0.1 (ng/mL) | 120 | 81 | <0.001 | <0.001 | 0.26 | 0.16 - 0.43 | ||
≥0.1 | 104 | 63 | |||||||
% of positive core | <40 | 176 | 74 | 0.553 | |||||
≥40 | 48 | 67 | |||||||
ADT before HIFU | <3 M | 165 | 74 | 0.422 | |||||
≥3 M | 59 | 70 | |||||||
HIFU device | Sonablate 500 | 59 | 65 | 0.049 | 0.014 | 1.85 | 1.14 - 2.97 | ||
version 4 | 165 | 76 |